MENGENAI EPISOD INI

Bahasa Inggeris
Amerika Syarikat

TRANSKRIP 🔗

CARI EPISOD LEPAS

Cari episod lepas bagi Breaking Down Biosimilars.

EPISOD LAIN DALAM PODCAST INI

When biosimilars were introduced into the US, there was much talk about how much money they could potentially save patients. Getting a biosimilar developed and approved by the US Food & Drug Administration (FDA) is not as rigorous or time-consuming as for a biologic … which was touted ...
In this episode, Zoe and Conner check in with several patients who’ve made the switch to a biosimilar to find out how they’re doing. Some patients taking a biosimilar have to travel to an infusion site to receive their medication, while others inject their medication at home. In thos ...
Biosimilars were first introduced into the US market about six years ago, but getting the all-important “patient buy-in” has been a slow process. Many patients are reluctant to switch to a biosimilar if they’re already happy taking a biologic. But another reason is the prolifer ...
Many patients have questions and may be reluctant to make the switch to biosimilars at first. In this episode, hosts Zoe Rothblatt and Conner Mertens talk to a few patients about their experiences starting a biosimilar. They discuss some of the hurdles they face, like overcoming hesitancy, getti ...
The introduction of biosimilars in the US has been hampered by unrealized cost savings, myths and misinformation, and patient hesitancy. Still, many medical professionals see much to be optimistic about in the next few years. New biosimilars will soon be approved for the US market, and expectati ...
Penafian: Podcast dan karya seni yang dibenamkan pada halaman ini adalah daripada Global Healthy Living Foundation, yang merupakan hak milik pemiliknya dan tidak bergabung dengan atau disokong oleh Listen Notes, Inc.